Jenni Mykkanen

Title: Innovations by Jenni Mykkanen

Introduction

Jenni Mykkanen is a prominent inventor based in Kuopio, Finland. She has made significant contributions to the field of gene therapy through her innovative patents. With a total of three patents to her name, Mykkanen is recognized for her work in ensuring the quality and safety of viral vectors used in gene therapy.

Latest Patents

Mykkanen's latest patents include a viral vector assay and a gene therapy vector contamination assay. The viral vector assay is a process designed to assay viral vectors manufactured by large-scale processes, ensuring that the resulting vectors maintain acceptable purity and potency. This process involves three different types of assays, each of which can be used independently or together to provide a comprehensive quality assurance system for viral vectors.

The gene therapy vector contamination assay addresses the potential issue of replication-competent viruses (RCVs) that may inadvertently form during the manufacturing of viral gene therapy vectors. Regulatory agencies require rigorous testing for the presence of these contaminants. Mykkanen's innovative approach utilizes digital PCR, which has proven to be faster and significantly more sensitive than traditional methods, allowing for the detection of as few as seven replication-competent adenoviruses in a sample.

Career Highlights

Mykkanen's career is marked by her dedication to advancing gene therapy technologies. Her work at Trizell Limited has positioned her as a key player in the field, where she continues to develop and refine methods for ensuring the safety and efficacy of viral vectors.

Collaborations

Throughout her career, Mykkanen has collaborated with notable colleagues, including Nigel Parker and Minna Hassinen. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Jenni Mykkanen's innovative contributions to gene therapy through her patents highlight her expertise and commitment to improving the safety of viral vectors. Her work continues to impact the field positively, paving the way for advancements in gene therapy applications.